| Year |
Citation |
Score |
| 2023 |
Béraud C, Bidan N, Lassalle M, Lang H, Lindner V, Krucker C, Masliah-Planchon J, Potiron E, Lluel P, Massfelder T, Allory Y, Misseri Y. A new tumorgraft panel to accelerate precision medicine in prostate cancer. Frontiers in Oncology. 13: 1130048. PMID 37305585 DOI: 10.3389/fonc.2023.1130048 |
0.304 |
|
| 2022 |
Firlej V, Soyeux P, Nourieh M, Huet E, Semprez F, Allory Y, Londono-Vallejo A, de la Taille A, Vacherot F, Destouches D. Overexpression of Nucleolin and Associated Genes in Prostate Cancer. International Journal of Molecular Sciences. 23. PMID 35562881 DOI: 10.3390/ijms23094491 |
0.304 |
|
| 2020 |
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, ... ... Allory Y, et al. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?. European Urology. PMID 32682615 DOI: 10.1016/J.Eururo.2020.07.002 |
0.35 |
|
| 2020 |
Mussat E, Jouinot A, Saldana C, Joly C, Allory Y, Nourieh M, Vordos D, Salomon L, Taille Adl, Tournigand C, Rousseau B. Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 38: 490-490. DOI: 10.1200/Jco.2020.38.6_Suppl.490 |
0.306 |
|
| 2019 |
Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, ... ... Allory Y, et al. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer. PMID 31882335 DOI: 10.1016/J.Clgc.2019.11.014 |
0.362 |
|
| 2019 |
Koutros S, Kogevinas M, Friesen MC, Stewart PA, Baris D, Karagas MR, Schwenn M, Johnson A, Monawar Hosain GM, Serra C, Tardon A, Carrato A, Garcia-Closas R, Moore LE, Nickerson ML, ... ... Allory Y, et al. Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. Environment International. 135: 105346. PMID 31864026 DOI: 10.1016/J.Envint.2019.105346 |
0.332 |
|
| 2019 |
Kamoun A, Reyniès A, Allory Y, Sjödahl G, Gordon Robertson A, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology. PMID 31563503 DOI: 10.1016/J.Eururo.2019.09.006 |
0.323 |
|
| 2019 |
Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I. : A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. Oncology Letters. 18: 3471-3480. PMID 31516565 DOI: 10.3892/Ol.2019.10706 |
0.348 |
|
| 2019 |
Drak Alsibai K, Vacher S, Meseure D, Nicolas A, Lae M, Schnitzler A, Chemlali W, Cros J, Longchampt E, Cacheux W, Pignot G, Callens C, Pasmant E, Allory Y, Bieche I. High Positive Correlations between and -/-/- Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an Bidirectional Promoter. Non-Coding Rna. 5. PMID 31438464 DOI: 10.3390/Ncrna5030044 |
0.347 |
|
| 2019 |
Mauffrey P, Tchitchek N, Barroca V, Bemelmans A, Firlej V, Allory Y, Roméo PH, Magnon C. Progenitors from the central nervous system drive neurogenesis in cancer. Nature. PMID 31092925 DOI: 10.1038/S41586-019-1219-Y |
0.389 |
|
| 2019 |
Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 8: e1581556. PMID 31069145 DOI: 10.1080/2162402X.2019.1581556 |
0.317 |
|
| 2019 |
Dufour F, Silina L, Neyret-Kahn H, Moreno-Vega A, Krucker C, Karboul N, Dorland-Galliot M, Maillé P, Chapeaublanc E, Allory Y, Stransky N, Haegel H, Menguy T, Duong V, Radvanyi F, et al. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. British Journal of Cancer. PMID 30765874 DOI: 10.1038/S41416-019-0397-6 |
0.352 |
|
| 2019 |
Rouanne M, Betari R, Radulescu C, Goubar A, Signolle N, Neuzillet Y, Allory Y, Marabelle A, Adam J, Lebret T. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. European Journal of Cancer (Oxford, England : 1990). 108: 111-119. PMID 30654296 DOI: 10.1016/J.Ejca.2018.12.010 |
0.374 |
|
| 2019 |
Lang H, Beraud C, Lassalle M, Lindner V, Soulié M, Gamé X, Rischmann P, Allory Y, Radvanyi F, Bernard-Pierrot I, Lluel P, Massfelder T. Abstract 1930: High specific characterization of patient-derived tumor xenograft models for accelerating drug development in muscle-invasive bladder cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1930 |
0.34 |
|
| 2019 |
Rhijn Bv, Mertens L, Mayr R, Bostrom P, Marquez M, Zwarthoff E, Boormans J, Abas C, Leenders Gv, Gotz S, Bertz S, Neuzillet Y, Sanders J, Broeks A, Heijden Mvd, ... ... Allory Y, et al. Pd52-02 Fgfr3 Mutations And Their Relation To Fgfr3 Expression And Clinical Outcome In A Large Radical Cystectomy Cohort: Implications For Anti-Fgfr3 Bladder Cancer Treatment? European Urology Supplements. 201. DOI: 10.1097/01.Ju.0000556958.45525.C0 |
0.307 |
|
| 2019 |
Dorta RB, Pineda S, Domínguez S, Rava M, Sirab N, Tardón A, Carrato A, Serra C, García-Closas R, Rothman N, Silverman D, Kogevinas M, Allory Y, Real FX, Malats N. Urothelial bladder cancer risk patterns according to tumor taxonomic subtypes European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)33302-0 |
0.341 |
|
| 2019 |
Rhijn BWGV, Mertens L, Mayr R, Bostrom P, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, Leenders GV, Neuzillet Y, Heijden MSVD, Jewett MAS, Stohr R, Zlotta AR, Eckstein M, ... ... Allory Y, et al. Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30597-4 |
0.334 |
|
| 2019 |
Almeida A, Saci Z, Pinskaya M, Firlej V, Bieche I, Meseure D, Londoño-Vallejo A, Taille ADL, Allory Y, Morillon A. Utilisation de longs ARN non codants vers un diagnostic urinaire du cancer de la prostate Bulletin De L Academie Nationale De Medecine. 203: 186-192. DOI: 10.1016/J.Banm.2018.03.001 |
0.382 |
|
| 2018 |
Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Nanor S, Delongchamps NB, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I. High prevalence of a hotspot of non-coding somatic mutations in intron 6 of GPR126 in bladder cancer. Molecular Cancer Research : McR. PMID 30401719 DOI: 10.1158/1541-7786.Mcr-18-0363 |
0.329 |
|
| 2018 |
Culine S, Allory Y, Pfister C. Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization. Translational Andrology and Urology. 7: 757-759. PMID 30211071 DOI: 10.21037/Tau.2018.06.11 |
0.354 |
|
| 2018 |
Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, Bergman CC, Auriault ML, Vordos D, Taille A, Culine S, Allory Y. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29467478 DOI: 10.1038/S41379-018-0023-9 |
0.323 |
|
| 2018 |
Pfister C, Gravis G, Pignot G, Flechon A, Soulie M, Chevreau C, Guy L, Laguerre B, Mottet N, Joly F, Henry-Amar M, Radvanyi F, Allory Y, Culine S. Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps530 |
0.317 |
|
| 2018 |
Rouanne M, Betari R, Radulescu C, Signolle N, Allory Y, Marabelle A, Adam J, Lebret T. Association of stromal lymphocyte infiltration with tumor invasion depth and high-grade T1 bladder cancer. Journal of Clinical Oncology. 36: 488-488. DOI: 10.1200/Jco.2018.36.6_Suppl.488 |
0.372 |
|
| 2018 |
Allory Y, Sirab N, Drubay D, Gentien D, Reyniès AD, Albaud B, Kamoun A, Soyeux P, Maille P, Lebret T, Benhamou S, Paoletti X, Radvanyi F. Evaluation of a 29 gene classifier for basal/non basal prediction in muscle-invasive bladder cancer FFPE samples. Journal of Clinical Oncology. 36: 467-467. DOI: 10.1200/Jco.2018.36.6_Suppl.467 |
0.324 |
|
| 2018 |
Lang H, Béraud C, Lassalle M, Bernard-Pierrot I, Lindner V, Allory Y, Soulié M, Gamé X, Rischmann P, Potiron E, Radvanyi F, Lluel P, Massfelder T. Abstract 1035: A comprehensive patient-derived tumor xenograft (PDX) collection representing the heterogeneity of kidney, prostate and bladder cancers Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1035 |
0.438 |
|
| 2018 |
Sroussi M, Lorcet M, Tardy MP, Guerin M, Estrade F, Delva R, Barthelemy P, Lavaud P, Neuzillet Y, Penel N, Houede N, Pouessel D, Mussat E, Goupil MG, Gauthier H, ... ... Allory Y, et al. Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy283.112 |
0.302 |
|
| 2018 |
Lang H, Beraud C, Lassalle M, Lluel P, Lindner V, Allory Y, Sirab N, Bernard-Pierrot I, Radvanyi F, Massfelder T. An extensive panel of patient-derived bladder cancer xenografts representing the various molecular subtypes of muscle-invasive bladder cancers (MIBC) European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)31901-8 |
0.364 |
|
| 2017 |
Gevaert T, Montironi R, Lopez-Beltran A, Van Leenders G, Allory Y, De Ridder D, Claessens F, Kockx M, Akand M, Joniau S, Netto G, Libbrecht L. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology. PMID 29032188 DOI: 10.1016/J.Semcancer.2017.10.004 |
0.386 |
|
| 2017 |
Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. European Urology Focus. PMID 28753865 DOI: 10.1016/J.Euf.2017.02.017 |
0.421 |
|
| 2017 |
Vinceneux A, Bruyère F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Rouprêt M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G. Ductal adenocarcinoma of the prostate: Clinical and biological profiles. The Prostate. PMID 28699202 DOI: 10.1002/Pros.23383 |
0.406 |
|
| 2017 |
Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, et al. Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice. 13: 414-421. PMID 28697319 DOI: 10.1200/Jop.2017.020909 |
0.32 |
|
| 2017 |
Duriez E, Masselon CD, Mesmin C, Court M, Demeure K, Allory Y, Malats N, Matondo M, Radvanyi F, Garin J, Domon B. Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine. Journal of Proteome Research. PMID 28287737 DOI: 10.1021/Acs.Jproteome.6B00979 |
0.35 |
|
| 2017 |
Verkarre V, Roussel H, Granier C, Tartour E, Allory Y. [Immunotherapy in uropathology]. Annales De Pathologie. PMID 28111042 DOI: 10.1016/J.Annpat.2016.12.015 |
0.377 |
|
| 2016 |
Vinceneux A, Bruyère F, Haillot O, Charles T, De la Taille A, Salomon L, Allory Y, Ouzzane I, Choudat L, Rouprêt M, Compérat E, Houede N, Beauval J, Fromont G. Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie. 26: 777-778. PMID 27969313 DOI: 10.1023/a:1013168323754 |
0.326 |
|
| 2016 |
Allory Y. [Bladder tumor histo-seminar - case 6: Invasive urothelial carcinoma, with inverted growth (UroA/FGFR3 molecular type)]. Annales De Pathologie. 36: 394-397. PMID 27838079 DOI: 10.1016/J.Annpat.2016.09.010 |
0.3 |
|
| 2016 |
Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Lebret T. A prospective multicenter study on bladder cancer: the COBLAnCE cohort. Bmc Cancer. 16: 837. PMID 27809812 DOI: 10.1186/S12885-016-2877-X |
0.353 |
|
| 2016 |
Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. Clinical Genitourinary Cancer. PMID 27554584 DOI: 10.1016/J.Clgc.2016.07.012 |
0.356 |
|
| 2016 |
Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, Gonzalez-Neira A, Marquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, et al. Inflammatory-related genetic variants in non-muscle invasive bladder cancer prognosis. A multi-marker Bayesian assessment. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27197286 DOI: 10.1158/1055-9965.Epi-15-0894 |
0.358 |
|
| 2016 |
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, ... ... Allory Y, et al. Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27091807 DOI: 10.1093/Annonc/Mdw170 |
0.344 |
|
| 2016 |
Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget. PMID 26993766 DOI: 10.18632/Oncotarget.8043 |
0.379 |
|
| 2016 |
Calderaro J, Masliah-Planchon J, Richer W, Planque L, Maille P, Taille Adl, Boussion H, Delattre O, Allory Y, Bourdeaut F. Abstract A29: Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A29 |
0.337 |
|
| 2016 |
Masson-Lecomte AJAM, Pineda S, Rava M, Carrato A, Tàrdon A, Silverman D, Rothman N, Garcia-Closas M, Chanock S, Allory Y, Real FX, Malats N. 1042 Association between PDL1 variants and muscle invasive bladder cancer prognosis European Urology Supplements. 15. DOI: 10.1016/S1569-9056(16)61043-6 |
0.327 |
|
| 2016 |
Masson-Lecomte A, Sirab N, Reyniès AD, Maillé P, Soyeux-Porte P, Vordos D, Lebret T, Benhamou S, Carrato A, Malats N, Real F, Taille ADL, Radvanyi F, Allory Y. 288 Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer European Urology Supplements. 15. DOI: 10.1016/S1569-9056(16)60290-7 |
0.334 |
|
| 2016 |
Amandine N, Masson-lecomte A, Mordoch J, Allory Y, Vordos D, Yiou R, Hoznek A, taille ADl, Salomon L. Le score de Gleason après prostatectomie totale de l’ISUP 2005 à l’ISUP 2014 : impact sur la survie sans récidive biologique : proposition d’un nouveau groupe pronostic Progres En Urologie. 26: 772. DOI: 10.1016/J.Purol.2016.07.210 |
0.327 |
|
| 2015 |
Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F. Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. Molecular & Cellular Oncology. 2: e999507. PMID 27308521 DOI: 10.1080/23723556.2014.999507 |
0.356 |
|
| 2015 |
Mason-lecomte A, maturana ELd, Pineda S, Rava M, Vordos D, Allory Y, Real F, Malats N. Association entre les variants de PDL1 et le pronostic des tumeurs de vessie non invasive du muscle : résultats issus d’une cohorte de cancers de vessie prospective multicentrique Progres En Urologie. 25: 758-759. PMID 26544283 DOI: 10.1016/J.Purol.2015.08.088 |
0.302 |
|
| 2015 |
Champy C, Semprez F, Sayed IE, Maille P, Soyeux P, Allory Y, Vacherot F, Taille ADL, Firlej V. Implication de la molécule X dans la récidive du cancer de prostate (CaP) localisé Progres En Urologie. 25: 727. PMID 26544219 DOI: 10.1016/J.Purol.2015.08.024 |
0.318 |
|
| 2015 |
Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, ... ... Allory Y, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics. 47: 1200-5. PMID 26343384 DOI: 10.1038/Ng.3399 |
0.3 |
|
| 2015 |
Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, de la Taille A, Vacherot F, Loric S, Fiet J. Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. The Journal of Steroid Biochemistry and Molecular Biology. 152: 89-100. PMID 25958048 DOI: 10.1016/J.Jsbmb.2015.05.002 |
0.33 |
|
| 2015 |
Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer. 121: 1422-30. PMID 25639219 DOI: 10.1002/Cncr.29233 |
0.446 |
|
| 2015 |
Bayoud Y, de la Taille A, Ouzzane A, Ploussard G, Allory Y, Yiou R, Vordos D, Hoznek A, Salomon L. International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. International Journal of Urology : Official Journal of the Japanese Urological Association. 22: 283-7. PMID 25612145 DOI: 10.1111/Iju.12681 |
0.323 |
|
| 2015 |
Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 6: 11994-2008. PMID 25596738 DOI: 10.18632/Oncotarget.2740 |
0.4 |
|
| 2015 |
Masson-Lecomte A, Xylinas E, Bouquot M, Sibony M, Allory Y, Comperat E, Zerbib M, de la Taille A, Rouprêt M. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World Journal of Urology. 33: 1087-93. PMID 25179011 DOI: 10.1007/S00345-014-1387-1 |
0.343 |
|
| 2015 |
Seisen T, Roudot-Thoraval F, Bosset PO, Beaugerie A, Allory Y, Vordos D, Abbou CC, De La Taille A, Salomon L. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores. World Journal of Urology. 33: 787-92. PMID 24985552 DOI: 10.1007/S00345-014-1348-8 |
0.403 |
|
| 2015 |
Saldana C, Salomon L, Rousseau B, Chaubet-Houdu M, Joly C, Ploussard G, Allory Y, Tournigand C, Taille Adl. Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial. Journal of Clinical Oncology. 33: 37-37. DOI: 10.1200/Jco.2015.33.7_Suppl.37 |
0.395 |
|
| 2014 |
Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Lebret T, ... ... Allory Y, et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Reports. 9: 1235-45. PMID 25456126 DOI: 10.1016/J.Celrep.2014.10.035 |
0.335 |
|
| 2014 |
Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. European Urology. 66: 1078-91. PMID 25151017 DOI: 10.1016/J.Eururo.2014.07.033 |
0.344 |
|
| 2014 |
Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, ... ... Allory Y, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine. 6: 244ra91. PMID 25009231 DOI: 10.1126/Scitranslmed.3008970 |
0.367 |
|
| 2014 |
Bessede T, Girodon E, Allory Y, Le Floch A, Leroy K, Salomon L. DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy. World Journal of Urology. 32: 899-904. PMID 24671609 DOI: 10.1007/S00345-014-1278-5 |
0.335 |
|
| 2014 |
Srinivasan H, Allory Y, Sill M, Vordos D, Alhamdani MS, Radvanyi F, Hoheisel JD, Schröder C. Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. Proteomics. 14: 1333-42. PMID 24610664 DOI: 10.1002/Pmic.201300320 |
0.374 |
|
| 2014 |
Ploussard G, Nicolaiew N, Mongiat-Artus P, Terry S, Allory Y, Vacherot F, Abbou CC, Desgrandchamps F, Salomon L, de la Taille A. Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. Prostate Cancer and Prostatic Diseases. 17: 157-62. PMID 24513649 DOI: 10.1038/Pcan.2014.2 |
0.366 |
|
| 2014 |
Ingels A, Ploussard G, Allory Y, Abbou C, de la Taille A, Salomon L. Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy. Urologia Internationalis. 92: 264-9. PMID 23919964 DOI: 10.1159/000351319 |
0.384 |
|
| 2014 |
Rouanne M, Rode J, Campeggi A, Allory Y, Vordos D, Hoznek A, Abbou CC, De La Taille A, Salomon L. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up. Scandinavian Journal of Urology. 48: 131-7. PMID 23883410 DOI: 10.3109/21681805.2013.813067 |
0.385 |
|
| 2014 |
Ploussard G, Nicolaiew N, Marchand C, Terry S, Vacherot F, Vordos D, Allory Y, Abbou CC, Salomon L, de la Taille A. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology. 65: 154-61. PMID 22698576 DOI: 10.1016/J.Eururo.2012.05.049 |
0.375 |
|
| 2014 |
Pouessel D, Thuaut AL, Vordos D, Houede N, Loriot Y, Chevreau C, Joly F, Beuzeboc P, Taille Adl, Bastuji-Garin S, Allory Y, Culine S. Long-term results and prognostic factors for survival following adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French retrospective multicenter cohort. Journal of Clinical Oncology. 32: 4549-4549. DOI: 10.1200/Jco.2014.32.15_Suppl.4549 |
0.323 |
|
| 2013 |
El Behi M, Krumeich S, Lodillinsky C, Kamoun A, Tibaldi L, Sugano G, De Reynies A, Chapeaublanc E, Laplanche A, Lebret T, Allory Y, Radvanyi F, Lantz O, Eiján AM, Bernard-Pierrot I, et al. An essential role for decorin in bladder cancer invasiveness. Embo Molecular Medicine. 5: 1835-51. PMID 24142880 DOI: 10.1002/Emmm.201302655 |
0.339 |
|
| 2013 |
Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia (New York, N.Y.). 15: 761-72. PMID 23814488 DOI: 10.1593/Neo.122070 |
0.386 |
|
| 2013 |
Masson-Lecomte A, Vordos D, Yiou R, Allory Y, Abbou C, Taille Adl, Salomon L. Résultats oncologiques de la cystectomie pour carcinome urothélial résistant au BCG comparés aux tumeurs invasives d’emblée☆ Progres En Urologie. 23: 456-463. PMID 23721705 DOI: 10.1016/J.Purol.2013.03.003 |
0.356 |
|
| 2013 |
Douard A, Taille Adl, Yiou R, Allory Y, Radulescu C, Vordos D, Hoznek A, Abbou CC, Salomon L. Impact pronostique des tumeurs localisées à l’apex prostatique ☆ Progres En Urologie. 23: 405-409. PMID 23628099 DOI: 10.1016/J.Purol.2013.02.003 |
0.323 |
|
| 2013 |
Ploussard G, Nicolaiew N, Marchand C, Terry S, Allory Y, Vacherot F, Abbou CC, Salomon L, de la Taille A. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial. Bju International. 111: 988-96. PMID 23452046 DOI: 10.1111/J.1464-410X.2012.11607.X |
0.39 |
|
| 2013 |
Nicolaiew N, Ploussard G, Chun FK, Xylinas E, Allory Y, Salomon L, de la Taille A. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol. Urologia Internationalis. 90: 306-11. PMID 23295308 DOI: 10.1159/000345603 |
0.404 |
|
| 2013 |
El Hajj A, Ploussard G, de la Taille A, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). Bju International. 111: 53-9. PMID 22726582 DOI: 10.1111/J.1464-410X.2012.11276.X |
0.386 |
|
| 2013 |
Ploussard G, de la Taille A, Terry S, Allory Y, Ouzaïd I, Vacherot F, Abbou CC, Salomon L. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urologic Oncology. 31: 1060-6. PMID 22300755 DOI: 10.1016/S1569-9056(12)60760-X |
0.417 |
|
| 2013 |
Xylinas E, Durand X, Ploussard G, Campeggi A, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L. Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: trifecta rate of achieving continence, potency and cancer control. Urologic Oncology. 31: 99-103. PMID 21719321 DOI: 10.1016/J.Urolonc.2010.10.012 |
0.313 |
|
| 2013 |
Allory Y, Bastuji-Garin S, Charles-Nelson A, Paoletti M, Shar L, Abbou C, Radulescu C, Salomon L. Caractéristiques histopathologiques après relecture systématique d’une série multicentrique et prospective de 590 pièces de prostatectomie radicale (2007–2011) Progres En Urologie. 23: 1024. DOI: 10.1016/J.Purol.2013.08.017 |
0.306 |
|
| 2013 |
Allory Y, Salomon L, Charles-Nelson A, Paoletti M, Shar L, Abbou C, Radulescu C, Bastuji-Garin S. Analyse de la concordance du stade tumoral, du score de Gleason et des limites chirurgicales après revue prospective des 590 pièces de prostatectomie de l’étude Propenlap Progres En Urologie. 23: 1021. DOI: 10.1016/J.Purol.2013.08.011 |
0.328 |
|
| 2012 |
Beauval J-, Roumiguié M, Doumerc N, Thoulouzan M, Huyghe É, Allory Y, Mazerolles C, Taille Adl, Malavaud B, Rischmann P, Soulié M, Salomon L. Migration des stades pathologiques après prostatectomie totale vers des tumeurs à plus haut risque de récidive : étude bicentrique comparative entre 2005 et 2010☆ Progres En Urologie. 22: 1015-1020. PMID 23178098 DOI: 10.1016/J.Purol.2012.07.013 |
0.332 |
|
| 2012 |
Amaral AF, Méndez-Pertuz M, Muñoz A, Silverman DT, Allory Y, Kogevinas M, Lloreta J, Rothman N, Carrato A, Rivas del Fresno M, Real FX, Malats N. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. Journal of the National Cancer Institute. 104: 1897-904. PMID 23108201 DOI: 10.1093/Jnci/Djs444 |
0.306 |
|
| 2012 |
Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salomon L, De La Taille A. Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy Urology. 80: 576-582. PMID 22925233 DOI: 10.1016/J.Urology.2012.04.066 |
0.304 |
|
| 2012 |
Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F, Goud B. Deregulation of Rab and Rab effector genes in bladder cancer. Plos One. 7: e39469. PMID 22724020 DOI: 10.1371/Journal.Pone.0039469 |
0.339 |
|
| 2012 |
Allory Y. [Diagnostic issues of prostate biopsies. Case 8. How to report the different grades observed on prostate biopsies?]. Annales De Pathologie. 32: 141-4. PMID 22520609 DOI: 10.1016/J.Annpat.2012.02.009 |
0.372 |
|
| 2012 |
Allory Y. [Diagnostic issues of prostate biopsies. Case 7. Gleason grade 4 adenocarcinoma, with ill-defined glands and poorly formed glandular lumina]. Annales De Pathologie. 32: 137-40. PMID 22520608 DOI: 10.1016/J.Annpat.2012.02.008 |
0.376 |
|
| 2012 |
Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, ... ... Allory Y, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. The Journal of Pathology. 227: 315-24. PMID 22422578 DOI: 10.1002/Path.4017 |
0.315 |
|
| 2012 |
Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A, de la Taille A. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. Bju International. 110: 43-9. PMID 22221521 DOI: 10.1111/J.1464-410X.2011.10682.X |
0.387 |
|
| 2012 |
Ploussard G, de la Taille A, Bayoud Y, Durand X, Terry S, Xylinas E, Allory Y, Vacherot F, Abbou CC, Salomon L. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. European Urology. 61: 356-62. PMID 21803484 DOI: 10.1016/J.Eururo.2011.07.041 |
0.308 |
|
| 2012 |
Ploussard G, Bayoud Y, Taille ADL, Durand X, Xylinas E, Allory Y, Vacherot F, Terry S, Claude A, Salomon L. 762 The risk of upstaged disease increased with the body mass index in low risk prostate cancer patients eligible for active surveillance European Urology Supplements. 11. DOI: 10.1016/S1569-9056(12)60759-3 |
0.35 |
|
| 2012 |
El AA, Caradec J, Nicolaiew N, Allory Y, De La Taille A, Vacherot F, Eschwege P, Manivet P, Kouyoumdjian J, Loric S. 538 PAR1 differential expression as a biomarker of prostate cancer progression European Urology Supplements. 11: e538-e538a. DOI: 10.1016/S1569-9056(12)60535-1 |
0.411 |
|
| 2012 |
Basset V, Semprez F, Allory Y, Taille ADL, Terry S. Intérêt d’une combinaison des biomarqueurs ERG et TFF3 dans le diagnostic et la caractérisation du cancer de prostate Progres En Urologie. 22: 835. DOI: 10.1016/J.Purol.2012.08.216 |
0.386 |
|
| 2012 |
Ouzaid I, Xylinas E, Allory Y, Vordos D, Abbou C, Salomon L, Taille ADL, Ploussard G. Indice de masse corporelle et cancer de la prostate : éléments histo-pronostiques sur les biopsies et les pièces de prostatectomies totales Progres En Urologie. 22: 769. DOI: 10.1016/J.Purol.2012.08.069 |
0.393 |
|
| 2012 |
Seisen T, Roudot-thoraval F, Bosset P-, Campeggi A, Vordos D, Abbou C-, Taille ADL, Salomon L, Allory Y, Hoznek A. Score de Gleason 6 sur les biopsies prostatiques. Comment améliorer la prédiction du score de Gleason sur la pièce de prostatectomie radicale Progres En Urologie. 22: 768. DOI: 10.1016/J.Purol.2012.08.067 |
0.31 |
|
| 2012 |
Basset V, Nicolaiew N, Ruffion A, Villers A, Houlgatte A, Allory Y, Salomon L, Vordos D, Abbou CC, Taille ADL. Analyse du profil de 10 654 patients candidats à une première série de biopsies prostatiques inclus sur dix ans dans quatre centres français Progres En Urologie. 22: 767. DOI: 10.1016/J.Purol.2012.08.065 |
0.309 |
|
| 2011 |
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery. 1: 487-95. PMID 22389870 DOI: 10.1158/2159-8290.Cd-11-0130 |
0.418 |
|
| 2011 |
Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology. 78: 90-8. PMID 21677472 DOI: 10.1159/000315543 |
0.349 |
|
| 2011 |
Xylinas E, Durand X, Campeggi A, Ploussard G, Allory Y, Vordos D, Hoznek A, Taille ADL, Abbou C-, Salomon L. Surveillance active du cancer de prostate ayant des critères de latence: les critères SURACAP sont-ils suffisants ? Progres En Urologie. 21: 264-269. PMID 21482401 DOI: 10.1016/J.Purol.2010.09.021 |
0.348 |
|
| 2011 |
Gillion N, Xylinas E, Durand X, Ploussard G, Vordos D, Allory Y, Hoznek A, de la Taille A, Abbou CC, Salomon L. Mid-term oncological control after laparoscopic radical cystectomy in men: a single-centre experience. Bju International. 108: 1180-4. PMID 21320272 DOI: 10.1111/J.1464-410X.2010.10054.X |
0.33 |
|
| 2011 |
Ploussard G, Xylinas E, Durand X, Ouzaïd I, Allory Y, Bouanane M, Abbou CC, Salomon L, de la Taille A. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. Bju International. 108: 513-7. PMID 21176083 DOI: 10.1016/S1569-9056(11)60841-5 |
0.353 |
|
| 2011 |
Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. Journal of the National Cancer Institute. 103: 47-60. PMID 21173382 DOI: 10.1093/Jnci/Djq470 |
0.31 |
|
| 2011 |
Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, de la Taille A. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. European Urology. 59: 422-9. PMID 21156337 DOI: 10.1016/J.Eururo.2010.11.044 |
0.416 |
|
| 2011 |
Alenda O, Ploussard G, Mouracade P, Xylinas E, de la Taille A, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World Journal of Urology. 29: 671-6. PMID 21107843 DOI: 10.1007/S00345-010-0620-9 |
0.335 |
|
| 2011 |
Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, De La Taille A. Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer Bju International. 107: 1400-1403. PMID 21050360 DOI: 10.1111/J.1464-410X.2010.09816.X |
0.396 |
|
| 2011 |
Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Bju International. 107: 1748-54. PMID 20883488 DOI: 10.1111/J.1464-410X.2010.09728.X |
0.357 |
|
| 2011 |
Descazeaud A, Weinbreck N, Robert G, Vacherot F, Abbou CC, Labrousse F, Allory Y, Rubin MA, de la Taille A. Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. Bju International. 108: E23-8. PMID 20840324 DOI: 10.1111/J.1464-410X.2010.09699.X |
0.336 |
|
| 2011 |
Ploussard G, de la Taille A, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L. Prospective evaluation of combined oncological and functional outcomes after laparoscopic radical prostatectomy: trifecta rate of achieving continence, potency and cancer control at 2 years. Bju International. 107: 274-9. PMID 20575978 DOI: 10.1111/J.1464-410X.2010.09462.X |
0.354 |
|
| 2011 |
Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, Taille ADL. 1008 The Pca3 Score Accurately Predicts Tumor Volume And Might Help In Selecting Prostate Cancer Patients For Active Surveillance European Urology Supplements. 10: 313-314. DOI: 10.1016/S1569-9056(11)60990-1 |
0.407 |
|
| 2011 |
Terry S, Maillé P, Ploussard G, Sirab N, Soyeux P, Bianco C, Salomon D, Taille Adl, Vacherot F, Allory Y. Expression et valeur pronostique de Cripto dans l’adénocarcinome de la prostate au stade hormono-naïf Annales De Pathologie. 31. DOI: 10.1016/J.Annpat.2011.09.050 |
0.376 |
|
| 2010 |
Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Research. 70: 9253-64. PMID 21045157 DOI: 10.1158/0008-5472.Can-10-1447 |
0.385 |
|
| 2010 |
Xylinas E, Ploussard G, Durand X, de La Taille A, Gillion N, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L. Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology. 76: 1194-8. PMID 20888624 DOI: 10.1016/J.Urology.2010.03.096 |
0.324 |
|
| 2010 |
Letouzé E, Allory Y, Bollet MA, Radvanyi F, Guyon F. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biology. 11: R76. PMID 20649963 DOI: 10.1186/Gb-2010-11-7-R76 |
0.308 |
|
| 2010 |
Paule B, Deslandes E, Le Mouel SP, Bastien L, Podgorniak MP, Allory Y, de la Taille A, Menashi S, Calvo F, Mourah S. Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. The International Journal of Biological Markers. 25: 112-5. PMID 20544684 DOI: 10.5301/Jbm.2010.2370 |
0.309 |
|
| 2010 |
Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avancès C, Allory Y, de la Taille A, Culine S, Blancou H, Cristol JP, Michel F, Sardet C, Fajas L. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Molecular Cancer Therapeutics. 9: 1740-54. PMID 20530718 DOI: 10.1158/1535-7163.Mct-09-1064 |
0.395 |
|
| 2010 |
Ploussard G, Azancot V, Nicolaiew N, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. Bju International. 106: 1293-7. PMID 20456338 DOI: 10.1111/J.1464-410X.2010.09361.X |
0.38 |
|
| 2010 |
Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou CC, Vordos D. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. The Journal of Urology. 183: 2161-4. PMID 20399454 DOI: 10.1016/J.Juro.2010.02.026 |
0.37 |
|
| 2010 |
Ploussard G, Bastien L, Descazeaud A, Robert G, Allory Y, Salomon L, Vordos D, Hoznek A, Yiou R, Abbou CC, de la Taille A. Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedure. Urologia Internationalis. 84: 147-52. PMID 20215817 DOI: 10.1159/000277590 |
0.404 |
|
| 2010 |
Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? The Journal of Urology. 183: 539-44. PMID 20006888 DOI: 10.1016/J.Juro.2009.10.009 |
0.371 |
|
| 2010 |
Ploussard G, Paule B, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Vacherot F, Abbou C, Culine S, Taille Adl. Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life Prostate Cancer and Prostatic Diseases. 13: 97-101. PMID 19935771 DOI: 10.1038/Pcan.2009.51 |
0.373 |
|
| 2010 |
Ploussard G, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Abbou CC, Vacherot F, de la Taille A. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. Bju International. 106: 86-90. PMID 19930177 DOI: 10.1111/J.1464-410X.2009.09080.X |
0.405 |
|
| 2010 |
Terry S, Ploussard G, Maillé P, Allory Y, Nicolaiew N, Soyeux P, Kheuang L, Culine S, Buttyan R, Taille Adl, Vacherot F. Abstract 5472: Class III beta-tubulin in castration resistant human prostate cancer Cancer Research. 70: 5472-5472. DOI: 10.1158/1538-7445.Am10-5472 |
0.411 |
|
| 2010 |
Ploussard G, Taille ADL, Allory Y, Vordos D, Hoznek A, Abbou C, Salomon L. 840 Prospective Evaluation Of Combined Oncologic And Functional Outcomes After Laparoscopic Radical Prostatectomy: Rate Of Achieving Continence, Potency And Cancer Control At 2 Years European Urology Supplements. 9: 268. DOI: 10.1016/S1569-9056(10)60823-8 |
0.325 |
|
| 2010 |
Ploussard G, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Vacherot F, Abbou C. 691 Pathological Findings And Psa Outcomes After Laparoscopic Radical Prostatectomy For High Risk Prostate Cancer European Urology Supplements. 9: 226-227. DOI: 10.1016/S1569-9056(10)60678-1 |
0.406 |
|
| 2010 |
Bessede T, Girodon E, Leroy K, Allory Y, Hoznek A, Taille Adl, Yiou R, Abbou C, Salomon L. 307 Investigation Of The Pt0 Prostate Cancer Phenomena: Dna-Comparison Of Biopsy-Sets And Radical Prostatectomy Specimens The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.370 |
0.388 |
|
| 2009 |
Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, Kheuang L, Coppolani E, Ali A, Bibeau F, Culine S, Buttyan R, Taille Adl, Vacherot F. Increased expression of class III β -tubulin in castration-resistant human prostate cancer British Journal of Cancer. 101: 951-956. PMID 19690549 DOI: 10.1038/Sj.Bjc.6605245 |
0.42 |
|
| 2009 |
Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A. The role of biopsy core number in selecting prostate cancer patients for active surveillance. European Urology. 56: 891-8. PMID 19683860 DOI: 10.1016/S1569-9056(10)60071-1 |
0.404 |
|
| 2009 |
Ploussard G, Dubosq F, Boublil V, Allory Y, de la Taille A, Vordos D, Hoznek A, Abbou CC, Salomon L. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. The Journal of Urology. 182: 1342-9. PMID 19683310 DOI: 10.1016/J.Juro.2009.06.050 |
0.396 |
|
| 2009 |
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. The Prostate. 69: 1774-80. PMID 19670242 DOI: 10.1002/Pros.21027 |
0.369 |
|
| 2009 |
De Laet K, de la Taille A, Ploussard G, Hoznek A, Vordos D, Yiou R, Allory Y, Azoulay S, Abbou C, Salomon L. Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsy. Bju International. 104: 616-20. PMID 19466953 DOI: 10.1111/J.1464-410X.2009.08468.X |
0.317 |
|
| 2009 |
Ploussard G, Plennevaux G, Allory Y, Salomon L, Azoulay S, Vordos D, Hoznek A, Abbou CC, de la Taille A. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World Journal of Urology. 27: 587-92. PMID 19373471 DOI: 10.1007/S00345-009-0413-1 |
0.389 |
|
| 2009 |
Rodríguez-Covarrubias F, Larré S, Dahan M, De La Taille A, Allory Y, Yiou R, Vordos D, Hoznek A, Abbou CC, Salomon L. Prognostic significance of microscopic bladder neck invasion in prostate cancer. Bju International. 103: 758-61. PMID 18990152 DOI: 10.1111/J.1464-410X.2008.08096.X |
0.424 |
|
| 2009 |
Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. European Urology. 55: 600-6. PMID 18597923 DOI: 10.1016/J.Eururo.2008.06.043 |
0.406 |
|
| 2009 |
Bernard‐Pierrot I, Dunois‐Larde C, Stransky N, Herault A, Lepage M, Ouerhani S, Abbou C, Laplanche A, Benhamou S, Lebret T, Allory Y, Radvanyi F. Abstract B92: P38 MAPK activation is critical for FGFR3‐induced cell transformation in human bladder carcinoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B92 |
0.332 |
|
| 2009 |
Bernard‐Pierrot I, Sugano G, Laé M, Battail C, Allory Y, Stransky N, Krumeich S, Donnadieu M, Abbou C, Benhamou S, Lebret T, Sastre‐Garau X, Amigorena S, Radvanyi F, Thery C. Abstract B175: Lactadherin/MFGE8 favors bladder tumor progression by promoting tolerogenic immune responses Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B175 |
0.342 |
|
| 2009 |
Perner S, Pflueger D, Rickman DS, Lafargue CJ, Svensson MA, Demichelis F, Stephan C, Dietel M, Fritzsche FR, Han B, Palanisamy N, Mehra R, Allory Y, Maille P, Taille ADL, et al. 785 Slc45a3 Is a Common Ets Family Fusion Partner in Prostate Cancer European Urology Supplements. 8: 317. DOI: 10.1016/S1569-9056(09)60773-9 |
0.389 |
|
| 2009 |
Ploussard G, Plennevaux G, Allory Y, Salomon L, Azoulay S, Vordos D, Hoznek A, Abbou CC, Taille Adl. Are Pin And Asap Diagnosed On Extended Prostate Biopsy Associated With The Same Risk Of Prostate Cancer On Rebiopsies The Journal of Urology. 181: 752-753. DOI: 10.1016/S0022-5347(09)62098-X |
0.397 |
|
| 2009 |
Robert G, Descazeaud A, Allory Y, Nicolaiew N, Maille P, Terry S, Sirab N, Bastien L, Vacherot F, Taille Adl. Inflammation In Prostatic Tissue Is Associated With Symptomatic Bph, Ipss And Prostate Volume! The Journal of Urology. 181: 504-504. DOI: 10.1016/S0022-5347(09)61424-5 |
0.355 |
|
| 2009 |
Ploussard G, Salomon L, Paule B, Allory Y, Vordos D, Hoznek A, Abbou CC, Culine S, Taille Adl. Using Adjuvant Chemo-Hormono-Therapy After Radical Prostatectomuy For Locally Advanced Prostate Cancer Patients Does Not Delay Continence Recovery And Has A Low Impact On Quality Of Life: Results Of Morbidity Evaluation In Pro 05 Phase Ii Randomized Trial The Journal of Urology. 181: 293-293. DOI: 10.1016/S0022-5347(09)60835-1 |
0.358 |
|
| 2009 |
Robert G, Descazeaud A, Allory Y, Vacherot F, Taille Adl. Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia European Urology Supplements. 8: 879-886. DOI: 10.1016/J.Eursup.2009.11.004 |
0.376 |
|
| 2008 |
Descazeaud A, Rubin MA, Hofer M, Setlur S, Nikolaief N, Vacherot F, Soyeux P, Kheuang L, Abbou CC, Allory Y, de la Taille A. BPH gene expression profile associated to prostate gland volume. Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 17: 207-13. PMID 18936709 DOI: 10.1097/Pdm.0B013E31816F6352 |
0.355 |
|
| 2008 |
Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Medina SGDd, Moutereau S, Maillé P, Soyeux P, Abbou C, Salomon L, Vacherot F, Taille AdL, Loric S, Allory Y. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. The Journal of Pathology. 216: 460-470. PMID 18825689 DOI: 10.1002/Path.2427 |
0.344 |
|
| 2008 |
Giton F, de la Taille A, Allory Y, Galons H, Vacherot F, Soyeux P, Abbou CC, Loric S, Cussenot O, Raynaud JP, Fiet J. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). The Journal of Steroid Biochemistry and Molecular Biology. 109: 158-67. PMID 18337090 DOI: 10.1016/J.Jsbmb.2007.10.005 |
0.343 |
|
| 2008 |
Allory Y, Audard V, Fontanges P, Ronco P, Debiec H. The L1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis Kidney International. 73: 751-758. PMID 18059459 DOI: 10.1038/Sj.Ki.5002640 |
0.389 |
|
| 2008 |
Rodriguez-Covarrubias F, Larré S, Dahan M, Taille ADL, Allory Y, Yiou R, Vordos D, Hoznek A, Abbou C, Salomon L. Invasion of bladder neck after radical prostatectomy: one definition for different outcomes. Prostate Cancer and Prostatic Diseases. 11: 294-297. PMID 17876340 DOI: 10.1038/Sj.Pcan.4501009 |
0.4 |
|
| 2007 |
Rouprêt M, Cancel-Tassin G, Comperat E, Fromont G, Sibony M, Molinié V, Allory Y, Triau S, Champigneulle J, Gaffory C, Larré S, de la Taille A, Richard F, Hamdy FC, Cussenot O. Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 2500-3. PMID 18006944 DOI: 10.1016/S1569-9056(08)60878-7 |
0.304 |
|
| 2007 |
Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3545-51. PMID 17575217 DOI: 10.1158/1078-0432.Ccr-06-2940 |
0.361 |
|
| 2007 |
Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ, Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. European Urology. 52: 430-5. PMID 17412489 DOI: 10.1016/J.Eururo.2007.02.062 |
0.394 |
|
| 2007 |
Gallina A, Karakiewicz PI, Walz J, Hutterer GC, Trinh QD, Saad F, Chemama S, Allory Y, Salomon L, Abbou CC, Taille ADL. 405 21-Core Initial Biopsy: Increasing Detection Rate Without Compromising The Ability To Predict Prostate Cancer At Biopsy European Urology Supplements. 6: 124. DOI: 10.1016/S1569-9056(07)60403-5 |
0.388 |
|
| 2007 |
Dahan M, Larré S, Vordos D, Taille ADL, Hoznek A, Yiou R, Allory Y, Abbou CC, Salomon L. 124 Invasion Of Bladder Neck After Radical Prostatectomy (Pt4): One Definition For Different Prognosis European Urology Supplements. 6: 53. DOI: 10.1016/S1569-9056(07)60123-7 |
0.311 |
|
| 2007 |
Taille ADL, Allory Y, Vacherot F, Terry S, Maille P, Campos JL, Salomon L, Vordos D, Larre S, Hoznek A, Rene Y, Abbou C, Paule B. 21 Adjuvant Androgen Deprivation And Chemotherapy For Patients With High Risk Prostate Cancer Progression After Radical Prostatectomy: Preliminary Study On Toxicity And Side Effects European Urology Supplements. 6: 28. DOI: 10.1016/S1569-9056(07)60021-9 |
0.417 |
|
| 2007 |
Campos JL, Allory Y, Chemama S, Larre S, Vordos D, Salomon L, Hoznek A, Yiou R, Abbou C, Taille ADL. 1960: Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy Protocol The Journal of Urology. 177: 650-650. DOI: 10.1016/S0022-5347(18)32120-7 |
0.392 |
|
| 2007 |
Giton F, Taille ADL, Allory Y, Vacherot F, Cussenot O, Abbou C, Raynaud JP, Fiet J. 1619: Plasma Estrogens in Newly Diagnosed Patients for Prostate Cancer The Journal of Urology. 177: 536-536. DOI: 10.1016/S0022-5347(18)31807-X |
0.383 |
|
| 2006 |
Berberian JP, Goeman L, Allory Y, Abbou CC, Salomon L. Adenocarcinoma of ileal neobladder 20 years after cystectomy. Urology. 68: 1343.e9-10. PMID 17141834 DOI: 10.1016/J.Urology.2006.09.014 |
0.329 |
|
| 2006 |
Descazeaud A, Rubin M, Chemama S, Larré S, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Chopin D, Abbou C, de la Taille A. Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World Journal of Urology. 24: 676-80. PMID 17089179 DOI: 10.1007/S00345-006-0134-7 |
0.391 |
|
| 2006 |
Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, Manivet P, Conti M, Vaubourdolle M, Cugnenc P, Loric S. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery. 139: 665-670. PMID 16701100 DOI: 10.1016/J.Surg.2005.10.012 |
0.304 |
|
| 2006 |
Terry S, Queires L, Gil-Diez-de-Medina S, Chen M, Taille Adl, Allory Y, Tran P, Abbou CC, Buttyan R, Vacherot F. Protocadherin-PC promotes androgen-independent prostate cancer cell growth. The Prostate. 66: 1100-1113. PMID 16637074 DOI: 10.1002/Pros.20446 |
0.343 |
|
| 2006 |
Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. The Prostate. 66: 1037-43. PMID 16598739 DOI: 10.1002/Pros.20405 |
0.366 |
|
| 2006 |
Allory Y, Commo F, Boccon-Gibod L, Sibony M, Callard P, Ronco P, Debiec H. Sulfated HNK-1 epitope in developing and mature kidney: a new marker for thin ascending loop of Henle and tubular injury in acute tubular necrosis. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 54: 575-84. PMID 16401697 DOI: 10.1369/Jhc.5A6791.2006 |
0.466 |
|
| 2006 |
Ménard Y, Guichard G, Hoznek A, Taille ADL, Yiou R, Vordos D, Allory Y, Abbou CC, Salomon L. Comparison Of Laparoscopic Radical Prostatectomy With And Without Previous Transurethral Prostate Resection European Urology Supplements. 5: 53. DOI: 10.1016/S1569-9056(06)60129-2 |
0.376 |
|
| 2006 |
Atmani AE, Allory Y, Moutereau S, Kouyoumdjian JC, Manivet P, Loric S. P6. Proteinases activated receptors: Expression and quantification in colon and prostate human cancer Ejc Supplements. 4: 29. DOI: 10.1016/J.Ejcsup.2006.04.066 |
0.38 |
|
| 2005 |
Lefèvre M, Couturier J, Sibony M, Bazille C, Boyer K, Callard P, Vieillefond A, Allory Y. Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. The American Journal of Surgical Pathology. 29: 1576-1581. PMID 16327429 DOI: 10.1097/01.Pas.0000184821.09871.Ec |
0.321 |
|
| 2005 |
Rubin MA, Allory Y, Molinié V, Leroy X, Faucon H, Vacherot F, Huang W, Kuten A, Salomon L, Rebillard X, Cussenot O, Abbou C, Taille Adl. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology. 66: 930-934. PMID 16286097 DOI: 10.1016/J.Urology.2005.07.036 |
0.366 |
|
| 2005 |
Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, Taille Adl. What Information are Urologists Extracting from Prostate Needle Biopsy Reports and What do They Need for Clinical Management of Prostate Cancer European Urology. 48: 911-915. PMID 16140457 DOI: 10.1016/J.Eururo.2005.07.011 |
0.406 |
|
| 2005 |
Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1190-7. PMID 15709188 |
0.419 |
|
| 2005 |
Taille ADL, Salomon L, Guichard G, Beley S, Faucon H, Allory Y, Patard JJ, Vordos D, Hoznek A, Abbou C. Risk Of Non-Significant Prostate Cancer In Prostate Cancer Patients Diagnosed By An Extended Prostate Needle-Biopsy Procedure And Treated By Radical Prostatectomy European Urology Supplements. 5: 201. DOI: 10.1016/S1569-9056(06)60721-5 |
0.419 |
|
| 2005 |
Descazeaud A, Rubin M, Allory Y, Salomon L, Burshardt M, Chopin D, Abbou C, Taille ADl. 1024 What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer European Urology Supplements. 4: 258. DOI: 10.1016/S1569-9056(05)81028-0 |
0.384 |
|
| 2005 |
Descazeaud A, Rubin M, Allory Y, Salomon L, Hofer M, Bismar T, Kim R, Chopin D, Abbou CC, Taille ADl. 610ZAG, zinc-alpha2-glycoprotein: Independent prognostic factor in prostate cancer European Urology Supplements. 4: 155. DOI: 10.1016/S1569-9056(05)80614-1 |
0.369 |
|
| 2005 |
Rubin MA, Allory Y, Huang W, Leroy X, Molinié V, Kuten A, Salomon L, Abbou C, Chopin DK, Taille ADL. 473: The Effects of Long Term Finasteride Treatment on Prostate Cancer Morphology The Journal of Urology. 173: 129-130. DOI: 10.1016/S0022-5347(18)34726-8 |
0.37 |
|
| 2004 |
Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, Taille Adl. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. Bjui. 94: 524-527. PMID 15329105 DOI: 10.1111/J.1464-4096.2004.04919.X |
0.35 |
|
| 2004 |
Descazeaud A, Salomon L, Allory Y, Hoznek A, Vordos D, Yiou R, Chopin D, Abbou C, Taille ADL. 864: Does a 21 Prostate Needle Biopsies Protocol Improve the Prediction of PT3 Status, Positive Surgical Margins and Tumor Localization on Radical Prostatectomy Specimen? The Journal of Urology. 171: 228-229. DOI: 10.1016/S0022-5347(18)38113-8 |
0.381 |
|
| 2003 |
Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard P, Paul P. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. The American Journal of Pathology. 162: 501-8. PMID 12547708 DOI: 10.1016/S0002-9440(10)63844-8 |
0.305 |
|
| Show low-probability matches. |